NCT02210663 - A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

July 31, 2016

Conditions

Advanced Solid Tumors

Interventions

DRUG

veliparib (ABT-888)

Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.

Trial Locations (3)

Site Reference ID/Investigator# 128056, Hidaka-shi

Site Reference ID/Investigator# 129976, Hyōgo

Site Reference ID/Investigator# 128057, Tokyo